EFFICACY OF DIFFERENT DESIGNS OF HORMONETHERAPY IN PATIENTS WITH BREAST CANCER DEPENDING ON MENSTRUAL STATUS, EXPRESSION OF STEROID HORMONES RECEPTORS AND HER2/NEU

Under the condition of application of indivi- dual designs of polychemotherapy, hormone- and biotherapy in complex treatment of patients with breast cancer stage T1-2NO-2M0 it is possible to attain satisfactory results of 3-year without relapse and total survival independently from Her2/neu expression. In patients with breast cancer in premenopause period and hormone-sensitive Her2/neu the method of option of suppression of ovarian function is application of Gozerelin In patients with breast cancer with Her2/neu in postmenopause period a considerable advantage of hormonetherapy by tamoxifen (5 years) comparing with administration of tamoxifen (2 years) with conversion to aromatase inhibitors (3 years) was not observed In patients with breast cancer with Her2/neu in postmenopause period the application of aromatase inhibitors during 5 years was efficacy and safety.



No comments » Add comment